SAMe (S-adenosyl-L-methionine, pronounced "sammy") has two identities. In Italy, a SAMe tablet called Samyr, first authorized in 1982, is a prescription medicine for depressive syndromes. In the United States, the same molecule became widely sold as a dietary supplement in 1999, and it now sits on store shelves next to fish oil and St. John's wort, marketed for mood and joint comfort.
A prescription label abroad sounds like strong evidence. The trials tell a more complicated story: older European studies, often with injected SAMe, looked as good as the antidepressants of their day, while most modern oral trials missed their main goal. Here is what the trials actually tested, in whom, and what it means for SAMe sold as a supplement.
The short version
- It is a prescription drug in Italy and a supplement in the US. A foreign drug approval is not evidence that a US supplement works. Canada's CANMAT guideline downgraded SAMe to a third-line option for depression in 2023, citing mixed recent trials.
- The older trials looked good. In two Italian trials published in 2002, oral and injected SAMe showed no significant difference from the tricyclic antidepressant imipramine, with fewer side effects. Many older trials used injections, which are absorbed far better than tablets.
- Modern oral trials mostly missed. A US trial of 189 adults found neither SAMe nor escitalopram beat placebo, and two of the three modern placebo-controlled trials we found that added SAMe to an antidepressant showed no significant benefit.
- The meta-analyses disagree. One 2024 analysis found a moderate effect for SAMe alone against placebo; another found no significant difference in any comparison.
- Labels need reading. SAMe is unstable, so it is sold as a salt. Check that the label states the SAMe ion amount, not just the salt weight.
- Not for bipolar disorder, and not with antidepressants on your own. SAMe can trigger mania, and there is a case report of serotonin syndrome when combined with an antidepressant. SAMe is not a treatment for depression and should not replace care. Never stop or change an antidepressant on your own, and ask your clinician first if you take levodopa or are pregnant. If you are thinking about suicide, call or text 988, the Suicide and Crisis Lifeline, in the US.
What SAMe is
SAMe is made in every cell from the amino acid methionine. It is the body's main methyl donor: it hands a small chemical group, a methyl group, to DNA, proteins, cell membrane fats and brain chemicals, including the reactions that make and break down serotonin, dopamine and noradrenaline. After it gives up its methyl group it becomes S-adenosylhomocysteine, which is broken down to homocysteine and recycled back to methionine with the help of folate and vitamin B12. That is why SAMe comes up alongside methylfolate, B12 and TMG in conversations about methylation.
The case for SAMe in depression grew out of that chemistry and some small human studies. In a 1990 study, SAMe in the spinal fluid was lower in patients with severe depression than in a neurological comparison group, and SAMe given by vein or by mouth raised spinal fluid levels, showing it reaches the brain. A 2000 study of 46 inpatients with severe depression found that about half had high homocysteine, and that group had lower folate, lower spinal fluid SAMe and lower levels of serotonin and dopamine breakdown products. That finding was in a folate-poor subgroup, and a 1994 review found no consistent changes in blood SAMe in psychiatric patients. These studies make SAMe plausible. They do not show that taking it relieves depression.
The evidence at a glance
| The claim | What was tested | Best evidence | Our read |
|---|---|---|---|
| SAMe works as well as antidepressants | SAMe against imipramine (a tricyclic) or escitalopram, mostly in older European trials, often injected | Two Italian trials of about 280 and 295 adults: no significant difference from imipramine, fewer side effects. The only SSRI comparison we found (189 adults): neither SAMe nor escitalopram beat placebo | No significant difference is not the same as proven equal, and the strongest trials used injections or older comparators |
| SAMe on its own beats placebo | Placebo-controlled trials, oral and injected | A 2024 meta-analysis (11 placebo-controlled trials within a 23-trial review): moderate effect (SMD -0.58), moderate certainty but high heterogeneity. A second 2024 meta-analysis: no significant difference. Cochrane 2016: very low quality, no clear difference | Uncertain. The pooled analyses disagree, and modern oral trials were mostly negative |
| It helps when added to an antidepressant | SAMe added to an antidepressant in people still depressed | One 73-person trial was positive (response 36.1% vs 17.6%). Trials of 234 and 107 people found no significant difference. Pooled add-on effect not significant | Not supported overall. One positive oral trial, not replicated |
| It works faster than antidepressants | Speed of improvement | An uncontrolled study of injected SAMe, small trials of injected SAMe, and a secondary analysis | Not shown in the main results of any controlled oral trial against an antidepressant; one single-site secondary analysis found SAMe ahead of escitalopram at weeks 2 to 6 |
| 800 to 1,600 mg a day is the right dose | Doses in trials | Oral trials mostly used 800 to 1,600 mg a day, up to 3,200 mg; injected trials 200 to 400 mg. Doubling to 3,200 mg in non-responders did no better than doubling placebo or escitalopram | A common trial range, not a proven dose |
| It is a prescription drug in Europe | Regulatory status | Prescription in Italy (Samyr, depressive syndromes) and listed as prescription-only in Germany; other national products are licensed for liver conditions | True in some countries. A foreign approval does not make the US supplement proven |
These summaries describe research in people with diagnosed depression, often under medical care. They are not claims about what a supplement does, and SAMe is not a treatment for depression. SMD is a standardized effect size. Do not stop or change an antidepressant on your own, and do not take SAMe with bipolar disorder except under a clinician's care. In a crisis, call or text 988, the Suicide and Crisis Lifeline, in the US.
The older European trials: injections and tricyclics
Much of SAMe's reputation comes from Italian research in the 1980s to early 2000s. Many of those trials used SAMe by injection into a muscle or vein, which matters: injected SAMe is almost completely absorbed, while swallowed SAMe survives digestion but much of it is removed by the liver before it reaches the general circulation (a Russian drug label puts oral bioavailability at about 5%, against about 95% by injection).
The two largest, published together in 2002, compared SAMe with imipramine, a tricyclic antidepressant. In one, 281 adults took 1,600 mg of oral SAMe or 150 mg of imipramine a day for six weeks. In the other, about 295 adults received 400 mg of SAMe by injection or imipramine for four weeks. Both found no significant difference in improvement, and significantly fewer side effects with SAMe. A separate 2002 paper on an injection trial of 293 adults, possibly the same trial, found the same.
Several smaller older studies were positive. In 80 postmenopausal women with depression, oral SAMe at 1,600 mg a day for 30 days beat placebo, with differences from day 10. An early government evidence review, from the US Agency for Healthcare Research and Quality in 2002, included 28 studies in its depression meta-analysis. Against placebo, SAMe was about 6 points better on the Hamilton depression scale at three weeks, which the reviewers called statistically and clinically significant, and it did not differ significantly from conventional antidepressants. It also noted that good dose-finding studies of oral SAMe had not been done.
Two caveats run through this era. Tricyclics have more side effects than modern antidepressants, so "fewer side effects than imipramine" is a lower bar. And the claim that SAMe works faster rests mainly on an uncontrolled study of injected SAMe in 195 people, small controlled trials of injected SAMe, and a secondary analysis, not on the main results of controlled oral trials. A 1992 trial in 40 people found that injected SAMe added to imipramine sped early improvement.
Modern oral trials
Since 2010, US and Australian researchers have tested oral SAMe in carefully run, double-blind trials. The results are mostly negative on their main goals.
- SAMe against escitalopram. In a 12-week US trial, 189 adults with major depression took SAMe (1,600 to 3,200 mg a day), the SSRI escitalopram, or placebo. All three groups improved by about 5 to 6 points, with no significant differences between them; remission was 28%, 28% and 17%. The trial failed for the prescription drug too, which points to a high placebo response rather than to SAMe matching escitalopram. At one site, SAMe did beat placebo, and a later analysis found an effect in men but not women; both were secondary looks. Doubling the dose to 3,200 mg a day in people who had not responded did no better than doubling placebo or escitalopram, and abdominal discomfort was common.
- SAMe on its own in milder depression. An 8-week Australian trial in 49 unmedicated adults with mild to moderate depression found a 3.8-point advantage for 800 mg a day (effect size 0.72) that was not statistically significant in this small trial (P = 0.13). Placebo response was 53%.
Small trials of combination products, such as SAMe 200 mg with a probiotic in 90 adults, reported benefits, but they cannot separate SAMe's effect from the other ingredients.
The 189-person trial was funded by the US National Institutes of Health, and its SAMe and matching placebo were supplied by a supplement maker.
What the meta-analyses say
Pooling the trials does not settle the question, because the analyses disagree.
- Limveeraprajak 2024 pooled 23 trials with 2,183 people. SAMe alone beat placebo by a moderate margin (SMD -0.58, 95% CI -0.93 to -0.23), rated moderate certainty, though results varied widely between trials (I-squared 68%). SAMe did not differ from antidepressants, and added to antidepressants it did not significantly beat placebo. Its authors concluded that SAMe alone may offer a moderate benefit and should be considered as a treatment option.
- Peng 2024 pooled 14 trials with 1,522 people and found no significant difference for SAMe against placebo alone, against imipramine or escitalopram, or against placebo as an add-on. Its authors read that as SAMe possibly giving relief similar to those drugs, with caution because of few studies and widely varying doses.
- Cochrane 2016 included 8 trials with 934 adults. SAMe alone against placebo showed no clear difference (2 trials, very low quality), and against imipramine no difference (low quality). As an add-on to SSRIs, one trial gave low-quality evidence favoring SAMe. The reviewers concluded no firm conclusions can be drawn.
Why the split? The analyses included different trials, mixed oral and injected SAMe, and covered doses from 200 to 3,200 mg a day over 2 to 12 weeks. A 2025 network meta-analysis produced much larger estimates for SAMe, but those rely heavily on indirect comparisons and are much larger than the direct estimates (for example SMD 0.06 against antidepressants in the 2024 analysis), so we give them little weight. A 2020 review called the results encouraging, and a 2017 American Psychiatric Association work group described the evidence as promising but limited.
SAMe added to antidepressants
The most cited modern trial is a positive one. In 2010, 73 adults who had not improved on an SSRI or SNRI added oral SAMe (target 800 mg twice a day) or placebo for six weeks. Response was 36.1% with SAMe against 17.6% with placebo, and remission 25.8% against 11.7%. It was small, from one research group, and the authors called it preliminary.
Later add-on trials did not replicate it:
- The Horizon study, the largest add-on trial we found in PubMed, gave 234 adults 800 mg of a proprietary SAMe formulation or placebo for six weeks. It found no significant difference on any of three depression scales; a benefit appeared only in a post hoc look at people enrolled early. Its authors were affiliated with the company developing the product.
- An 8-week Australian trial in 107 people still depressed on medication found no significant difference with 800 mg a day (response 54.3% vs 50.0%). One participant had symptoms resembling serotonin syndrome.
A separate small 2026 trial in 31 adults added 1,200 mg to trauma-focused therapy, not to a drug, and found no significant difference in symptoms. Pooled across five add-on trials in the 2024 meta-analysis, the effect was not significant (SMD -0.22). So among placebo-controlled oral add-on trials, the one encouraging result has not been replicated. Small open-label studies were positive, and a 2016 review of adjunctive nutraceuticals, written before the later negative trials, judged the evidence supportive.
Guidelines and drug status
- CANMAT (Canada). In 2016, SAMe was recommended as a "second-line adjunctive treatment" for mild to moderate depression, with oral doses often at 800 to 1,600 mg a day. In its 2023 update the group wrote that, owing to mixed findings in recent trials, "SAM-e is now downgraded to a third-line treatment."
- WFSBP and CANMAT taskforce, 2022. A clinician guideline on nutraceuticals gave adjunctive SAMe a weak recommendation and listed SAMe on its own as not currently recommended.
- NIH (NCCIH). A 2021 clinical digest states that current research does not support SAMe for treating depression.
- Drug status abroad. In Italy, Samyr (200 mg gastro-resistant tablets, first authorized in 1982) is a prescription medicine for depressive syndromes, while other Italian SAMe brands are licensed for liver bile-flow problems (cholestasis). Ademetionine is the drug name for SAMe. Germany lists ademetionine as prescription-only, although no German product appears on the European Medicines Agency's 2026 list of national authorizations. In Russia, SAMe injections carry a depression indication, but Heptral 400 mg tablets are now sold without a prescription for liver conditions only. There is no Europe-wide approval.
The thread: where SAMe has a place in guidelines, it is a lower-priority option chosen by a clinician. A medicine licensed in one country, made to drug standards, is not the same thing as a US supplement, and no US supplement may claim to treat depression.
Reading a SAMe label
SAMe is chemically fragile. It breaks down quickly in moisture and at neutral pH, so it is sold as a stabilized salt, usually SAMe tosylate disulfate (also called disulfate tosylate) or SAMe butanedisulfonate. That creates the main label trap: the salt weighs roughly twice as much as the SAMe it carries.
| What the label says | What it means | What to look for |
|---|---|---|
| "400 mg SAMe (from 800 mg SAMe tosylate disulfate)" | 400 mg of active SAMe, delivered by about 800 mg of salt | This is the clear way to label it |
| Only a salt weight, such as "800 mg SAMe tosylate" | The SAMe content may be about half the number shown | Look for a "net," "yield" or "ion" amount |
| Enteric-coated tablets in foil blisters | Protects SAMe from moisture and stomach acid | Keep tablets in the blister until use; the Italian drug label says not to use tablets that turn brownish |
| Capsules without enteric coating | Some brands use other stabilization | Check storage instructions and testing |
Label checks describe product quality, not whether SAMe helps mood; SAMe is not a treatment for depression. Do not combine it with an antidepressant or stop or change one without your prescriber, and avoid it with bipolar disorder unless a clinician is supervising. Ask your clinician first if you take levodopa or are pregnant. In a crisis, call or text 988, the Suicide and Crisis Lifeline, in the US.
Bioavailability is low by mouth. Swallowed SAMe is absorbed but largely removed by the liver on its first pass, and in a small 1983 study no rise in blood SAMe was seen after oral doses in healthy people. Later studies did measure raised blood levels on 1,600 mg a day. Injected SAMe, used in many older trials, is almost fully absorbed. The Italian drug label advises taking tablets apart from meals, though a 2022 study of one tablet found higher absorption with food, so the advice is not settled.
Quality has improved. Independent testing by ConsumerLab found that only 7 of 13 brands contained their labeled amount in 2000, partly because some counted the salt weight. In 2016, one of 10 products had only 77% of its listed SAMe, and in its 2024 review all 11 products tested contained their claimed amount and form. SAMe is also expensive: ConsumerLab reported 47 cents to over $2 for a 400 mg dose, so the 800 to 1,600 mg a day used in trials can cost several dollars a day.
If you are comparing methylation supplements, our guides to methylfolate and TMG cover the other parts of the same cycle.
Safety and who should be careful
- Depression needs professional care. SAMe is not a treatment for depression and should not replace therapy or medication, or delay seeing a clinician. If you are having thoughts of suicide or self-harm, call or text 988 (the Suicide and Crisis Lifeline) in the US, or your local emergency number.
- Bipolar disorder. SAMe can trigger mania or hypomania. NIH says it may not be safe for people with bipolar disorder; the Italian drug label advises against it and the Russian label lists it as a contraindication.
- Antidepressants and other serotonin-raising products. There is a published case of serotonin syndrome with SAMe and the antidepressant clomipramine (a 2017 review judged it most likely related to a rapid clomipramine dose increase), and NIH notes possible interactions with antidepressants, L-tryptophan and St. John's wort. Do not combine them, or stop or change an antidepressant, without your prescriber.
- Parkinson's disease. NIH says SAMe may decrease the effect of levodopa. NIH does not describe the evidence behind this, so ask your neurologist first.
- Weakened immune system. NIH notes a theoretical concern because the organism behind Pneumocystis pneumonia relies on SAMe.
- Pregnancy. Safety in pregnancy has not been established for mood use.
- Inherited methionine-cycle disorders. Drug labels list genetic disorders that cause homocystinuria or high homocysteine as a reason not to use SAMe, and advise checking B12 and folate in people at risk of deficiency.
Mania, in numbers. The Cochrane review counted two reports of mania or hypomania among 441 people taking SAMe. In a 1989 study, 9 of 11 people with bipolar disorder treated with SAMe, by vein or by mouth, switched into an elevated mood, while no one with unipolar depression did. In a 2004 study of 15 healthy volunteers taking up to 1,600 mg a day, one developed a brief mixed manic state and recovered within three days of stopping.
Everyday side effects. NIH describes side effects as usually minor, such as nausea or digestive upset. In the 189-person US trial, 19% on SAMe reported stomach discomfort and 20% diarrhea. The Italian drug label also lists headache, anxiety and insomnia, and the Russian label notes that anxiety can appear or worsen.
Homocysteine. Because SAMe is converted to homocysteine, some worry it could raise levels. In a 15-person study at 1,600 mg a day for four weeks, no one developed high homocysteine, and in a substudy of the 73-person add-on trial, total homocysteine did not rise significantly within the SAMe group, although levels differed between groups both before and after treatment. Drug labels note that SAMe can falsely raise homocysteine results on some lab tests, so tell your clinician you take it.
For the wider picture on supplements and mood, see our low mood supplement hub, our reviews of omega-3 for mood and 5-HTP, and our guide to supplement and drug interactions.
Frequently asked questions
Does SAMe work for depression?
The evidence is mixed. Older European trials, many using injected SAMe, found it performed similarly to the antidepressant imipramine, and a 2024 meta-analysis found a moderate effect for SAMe alone against placebo. But a second 2024 meta-analysis found no significant difference in any comparison, most modern oral trials missed their main goal, and Canada's CANMAT guideline downgraded SAMe to a third-line option in 2023. SAMe is not a treatment for depression and should not replace therapy or medication. Never stop or change an antidepressant on your own, and avoid SAMe with bipolar disorder unless a clinician is supervising. If you are in crisis, call or text 988, the Suicide and Crisis Lifeline, in the US.
Is SAMe as good as antidepressants?
That has not been shown. In older trials, mostly against the tricyclic imipramine and often with injected SAMe, there was no significant difference, which is not the same as proving SAMe equal. In the only trial against a modern SSRI that we found, 189 adults took SAMe, escitalopram or placebo, and neither SAMe nor escitalopram beat placebo. Do not stop or switch an antidepressant on your own, and talk with your prescriber before trying SAMe.
Can I take SAMe with my antidepressant?
Only with your prescriber's agreement. There is a published case of serotonin syndrome when SAMe was combined with the antidepressant clomipramine, and NIH notes possible interactions with antidepressants, L-tryptophan and St. John's wort. As an add-on, one 73-person trial was positive but two larger later trials found no significant difference. Never stop or change an antidepressant on your own, and do not use SAMe with bipolar disorder unless a clinician is supervising.
How much SAMe was used in studies?
Oral trials mostly used 800 to 1,600 mg a day, rising to 3,200 mg in one US trial, and injected trials used 200 to 400 mg; a Canadian guideline described 800 to 1,600 mg a day by mouth as a common range. No dose is proven: doubling to 3,200 mg a day in people who had not responded did no better than doubling placebo or escitalopram, and a 2002 government review noted that good dose-finding studies of oral SAMe had not been done. Many positive older trials used injected SAMe, which is absorbed far better than tablets. These are research doses, not dosing advice; any use for mood should be set by your clinician.
Is SAMe a prescription drug?
In some countries. In Italy, a SAMe tablet called Samyr, first authorized in 1982, is a prescription medicine for depressive syndromes, and other Italian SAMe products are licensed for liver bile-flow problems. Germany lists it as prescription-only. In the United States it is sold as a dietary supplement, and a foreign drug approval is not evidence that a US supplement works.
What are the side effects of SAMe?
NIH describes side effects as usually minor, such as nausea or digestive upset. In a 189-person trial, about one in five people on SAMe reported stomach discomfort or diarrhea, and drug labels also list headache, anxiety and insomnia. The most serious concern is mania or hypomania, especially in people with bipolar disorder, and there is a case report of serotonin syndrome with an antidepressant.
Why is SAMe sold in blister packs?
SAMe is chemically unstable and breaks down with moisture, so it is sold as a stabilized salt, often in enteric-coated tablets sealed in foil blisters. The Italian drug label says to remove tablets just before use and not to use tablets that have turned brownish. Because the salt weighs about twice as much as the SAMe it carries, check that the label states the SAMe amount, not only the salt weight.
Who should not take SAMe?
People with bipolar disorder should not use it except under a clinician's care, because it can trigger mania. People taking antidepressants or other serotonin-raising products, people with Parkinson's disease on levodopa, people with a weakened immune system, and anyone pregnant should talk with their clinician first, since safety in pregnancy has not been established. Drug labels also rule it out for people with inherited disorders that cause homocystinuria or high homocysteine.
The bottom line
SAMe has a real role in brain chemistry, and in Italy it is a prescription medicine for depressive syndromes, though a foreign approval is not evidence that a US supplement works. Its strongest results come from older European trials, many using injections, in which it showed no significant difference from the tricyclic imipramine. Modern oral trials mostly missed their main goals, the one positive add-on trial was not replicated, the meta-analyses disagree, and Canada's CANMAT group moved it to third-line in 2023.
So the evidence does not show that SAMe relieves depression. Where guidelines mention it at all, it is a lower-priority option that a clinician chooses, not a supplement to start on your own. It is not a treatment for depression, and it should not be combined with an antidepressant or used with bipolar disorder without your prescriber. Never stop or change an antidepressant on your own, and ask your clinician first if you take levodopa or are pregnant. If you do buy it, check that the label states the SAMe content rather than the salt weight. If your mood has been low for weeks, the best first step is to talk with a health professional, and if you are in crisis, call or text 988, the Suicide and Crisis Lifeline, in the US.